Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept

Table 2

Baseline characteristics of enrolled ranibizumab patients.

Patients	RPE loss (mm^2)				Number of injections (N)
	First year	Second year	Third year	Fourth year	Total	Since RPE loss, 36 months
P1	0.29	0.31	0.59	0.90	29	18
P2	0.31	0.34	0.36	0.38	47	20
P3	0.06	0.17	0.21	0.35	20	6
P4	0.67	2.78	4.54	5.45	6	3
P5	0.08	0.54	1.62	2.84	21	16
P6	0.15	0.29	0.44	0.50	31	21
P7	0.45	0.48	0.85	1.33	7	2
P8	0.65	2.49	3.58	4.11	26	18
P9	0.40	0.75	1.17	1.85	37	26
P10	0.12	0.55	1.23	2.58	35	18
P11	0.39	0.55	0.70	0.88	30	23
P12	0.36	0.40	0.42	0.50	31	22
P13	0.08	0.65	2.80	6.64	44	22
P14	0.32	0.72	1.02	1.52	27	19
P15	0.26	0.36	0.41	0.42	49	19
P16	0.72	0.98	1.33	1.71	27	23
P17	0.33	0.58	0.70	0.98	25	20
P18	0.22	0.49	1.38	2.53	22	12
P19	0.56	0.68	0.86	1.35	25	21
P20	0.35	2.14	5.10	8.51	18	15
P21	0.15	0.16	0.19	0.24	27	18
P22	0.98	1.33	1.61	1.96	39	31